PureTech Health PLC 2023 AR2
The report highlights PureTech Health's strategic and clinical progress in 2023, including the launch of two new Founded Entities, Seaport Therapeutics and Gallop Oncology. The company advanced its lead internal program, LYT-100, for idiopathic pulmonary fibrosis into a Phase 2b clinical trial, with topline results expected in late 2024. Financially, PureTech secured $100 million upfront from a royalty agreement with Royalty Pharma for KarXT and ended the year with $327.1 million in consolidated cash and short-term investments. On the ESG front, the company maintained gender parity at the board level and achieved significant energy and emissions reductions at its LEED Silver-certified Boston headquarters.
Company: PureTech Health PLC
Sector: Professional & technical services
Country: United States
Year: 2023
Type: AR2
Pages: 228
Back to company
PureTech Health PLC
Annual Report And Accounts
The report highlights PureTech Health's strategic and clinical progress in 2023, including the launch of two new Founded Entities, Seaport Therapeutics and Gallop Oncology. The company advanced its lead internal program, LYT-100, for idiopathic pulmonary fibrosis into a Phase 2b clinical trial, with topline results expected in late 2024. Financially, PureTech secured $100 million upfront from a royalty agreement with Royalty Pharma for KarXT and ended the year with $327.1 million in consolidated cash and short-term investments. On the ESG front, the company maintained gender parity at the board level and achieved significant energy and emissions reductions at its LEED Silver-certified Boston headquarters.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Total Waste
Women on Board
Women in Management
Employees